Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...
Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback